Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP Sells $365,317.56 in Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP David Sponsel sold 33,732 shares of the stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $10.83, for a total transaction of $365,317.56. Following the transaction, the executive vice president now owns 668,977 shares of the company’s stock, valued at $7,245,020.91. The trade was a 4.80 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

David Sponsel also recently made the following trade(s):

• On Monday, February 24th, David Sponsel sold 12,946 shares of Alphatec stock. The stock was sold at an average price of $10.73, for a total transaction of $138,910.58.
• On Monday, February 3rd, David Sponsel sold 36,256 shares of Alphatec stock. The stock was sold at an average price of $11.42, for a total transaction of $414,043.52.
• On Monday, January 13th, David Sponsel sold 58,283 shares of Alphatec stock. The stock was sold at an average price of $10.71, for a total transaction of $624,210.93.
• On Friday, January 10th, David Sponsel sold 238 shares of Alphatec stock. The stock was sold at an average price of $10.00, for a total transaction of $2,380.00.

Alphatec Price Performance

Shares of ATEC opened at $9.56 on Thursday. The firm has a market capitalization of $1.38 billion, a PE ratio of -7.47 and a beta of 1.39. The company’s 50-day moving average is $10.94 and its 200-day moving average is $8.69. Alphatec Holdings, Inc. has a fifty-two week low of $4.88 and a fifty-two week high of $14.88. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings data on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.04). Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. The company had revenue of $176.79 million during the quarter, compared to the consensus estimate of $172.74 million. Equities analysts forecast that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Hedge Funds Weigh In On Alphatec

Hedge funds have recently bought and sold shares of the business. R Squared Ltd bought a new position in Alphatec during the fourth quarter worth about $29,000. Comerica Bank increased its position in Alphatec by 66.8% during the fourth quarter. Comerica Bank now owns 3,116 shares of the medical technology company’s stock worth $29,000 after acquiring an additional 1,248 shares during the period. Nisa Investment Advisors LLC increased its position in Alphatec by 973.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock worth $43,000 after acquiring an additional 4,234 shares during the period. Quarry LP increased its position in Alphatec by 79.2% during the fourth quarter. Quarry LP now owns 5,374 shares of the medical technology company’s stock worth $49,000 after acquiring an additional 2,375 shares during the period. Finally, Newton One Investments LLC bought a new position in Alphatec during the fourth quarter worth about $50,000. 66.35% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Alphatec in a research report on Tuesday, January 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 price target on shares of Alphatec in a research report on Thursday, February 27th. StockNews.com raised shares of Alphatec from a “sell” rating to a “hold” rating in a research report on Friday, February 28th. Piper Sandler upped their price target on shares of Alphatec from $12.00 to $13.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. Finally, Barclays upped their price target on shares of Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 22nd. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $17.67.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.